Technology
R&D Capability
Research Platform
Reinovax's R&D center has a lab space of 2,200 square meters. It empowers the ability in various research technologies including gene engineering, cultivation and fermentation, separation and purification, bacterial polysaccharide technology, molecular coupling, immune evaluation, quality evaluation, adjuvant technology, and mRNA technology, which serves as a solid foundation for the R&D of novel vaccines and protein therapeutics.
Three Core Research Platforms
Three core technology platforms
ZiPS Platform
Polysaccharide and Conjugation Technology
Bacterial Polysaccharide Technology
Polysaccharide-Protein Conjugation Technology
ZiCP Platform
Carrier Protein-Based Immune Enhancement
Induction of Specific Antibodies and Mitigation of Immunosuppression via ZiCPTM Technology
ZiRP Platform
Recombinant Protein Technology
Exhibition
Exhibition
- Early R&D
- Pilot-scale Process Production
- GMP manufacturing
Reinovax WeChat official account
Friendship link: Changchun High-tech Group